1. BRCA1 Promoter Hypermethylation is Associated with Good Prognosis and Chemosensitivity in Triple-Negative Breast Cancer
    William Jacot et al, 2020, Cancers CrossRef
  2. Prognostic epigenetics
    Adriana Fodor et al, 2021, Medical Epigenetics CrossRef
  3. CDH22 hypermethylation is an independent prognostic biomarker in breast cancer
    Esperanza Martín-Sánchez et al, 2017, Clinical Epigenetics CrossRef
  4. Levels of DNA Methylation Vary at CpG Sites across the BRCA1 Promoter, and Differ According to Triple Negative and “BRCA-Like” Status, in Both Blood and Tumour DNA
    Sarah L. Daniels et al, 2016, PLOS ONE CrossRef
  5. Hypermethylation of CDKN2A exon 2 in tumor, tumor-adjacent and tumor-distant tissues from breast cancer patients
    Melanie Spitzwieser et al, 2017, BMC Cancer CrossRef
  6. Trojan-Like Peptide Drug Conjugate Design and Construction for Application in Treatment of Triple-Negative Breast Cancer
    Chuanguang Xiao et al, 2021, Journal of Biomedical Nanotechnology CrossRef
  7. CHL1 hypermethylation as a potential biomarker of poor prognosis in breast cancer
    Esperanza Martín-Sánchez et al, 2017, Oncotarget CrossRef